US Court Restricts Mail Delivery of Abortion Pill Mifepristone, Impacting Access Nationwide

A recent ruling by the Fifth Circuit Court of Appeals has temporarily halted the FDA’s 2023 regulation allowing the abortion pill mifepristone to be mailed, reinstating the requirement that patients obtain the medication in person. This decision significantly limits access to medication abortion, especially in states where abortion is banned.

The ruling stems from a lawsuit by Louisiana and directly challenges the FDA’s efforts to expand telemedicine access to abortion pills, a method used by millions of women in the US. The move raises concerns about the future of abortion access amid ongoing legal battles and state-level restrictions.

What the Court’s Decision Means for Abortion Access

The Fifth Circuit Court’s order pauses the FDA’s permanent lifting of the in-person dispensing requirement for mifepristone, a change originally made during the Covid-19 pandemic to facilitate safer access. This ruling forces patients to visit clinics or pharmacies in person, a barrier that disproportionately affects those in rural areas, people facing intimate partner violence, and individuals with disabilities.

"This decision defies clear science and settled law and advances an anti-abortion agenda that is deeply unpopular with the American people,"—Julia Kaye, ACLU attorney

Background: The FDA’s Expanded Access to Mifepristone

Mifepristone, approved in 2000 for terminating pregnancies up to seven weeks and later extended to ten weeks, is the first of a two-pill regimen used in medication abortions. The FDA’s 2021 decision to allow mailing of the pill during the pandemic was made to reduce health risks and improve access. In 2023, this change was made permanent, enabling telemedicine providers to send the medication directly to patients.

• Mifepristone blocks progesterone, essential for pregnancy continuation.
• Misoprostol, the second pill, induces uterine contractions to complete the abortion.
• Over 3.7 million women have used mifepristone in the US since 2000.
• The medication regimen is about 95% effective with minimal need for follow-up care.

Legal and Political Reactions to the Ruling

Louisiana’s Attorney General praised the ruling as a victory for unborn children, framing the FDA’s policy as facilitating deaths. Conversely, New York’s Attorney General reaffirmed her state’s commitment to protecting abortion access, emphasizing that medication abortion remains legal and essential in New York despite the appellate court’s decision.

"Restrictions on abortion care are restrictions on life-saving health care. This decision puts lives at risk,"—New York Attorney General Letitia James

What Lies Ahead for Medication Abortion Access?

The ruling overrides a lower court’s pause on the case and signals ongoing legal challenges to abortion pill access. With the Supreme Court having left room for states to impose restrictions post-2022, the future of telemedicine abortion access remains uncertain. Advocates warn that limiting mail-order options will exacerbate disparities in reproductive healthcare, especially for vulnerable populations.

As the case progresses, states will continue to diverge in their abortion policies, making access increasingly dependent on geography. The debate over mifepristone’s availability highlights the broader national conflict over reproductive rights and healthcare equity.